AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2015
Mar 18, 2015
30583_dirs_2015-03-18_d96dabb7-879d-4c99-b391-b9ee905a3ad3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2015-03-16
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-03-16 | Common Stock | S | 1000 | $123.477 | Disposed | 35258 | Indirect |
| 2015-03-17 | Common Stock | S | 1000 | $124.866 | Disposed | 34258 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 254757 | Direct |
Footnotes
F1: Trade made pursuant to a 10b5-1 plan executed March 2, 2015.
F2: The price in column 4 is an average weighted price. The price actually received ranged from $121.98 to $124.52. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
F3: The reporting person an his spouse act as trustees for the Bienaime Family Trust
F4: The price in column 4 is an average weighted price. The price actually received ranged from $123.74 to $126.26. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.